Patents Assigned to FOSUN ORINOVE PHARMATECH, INC.
  • IRE-1? inhibitors
    Patent number: 11337956
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: May 24, 2022
    Assignee: Fosun Orinove Pharmatech, Inc.
    Inventors: Qingping Zeng, Andras Toro, John Bruce Patterson, Warren Stanfield Wade, Zoltan Zubovics, Yun Yang, Zhipeng Wu
  • IRE-1? inhibitors
    Patent number: 10357475
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: July 23, 2019
    Assignee: Fosun Orinove PharmaTech, Inc.
    Inventors: Qingping Zeng, Andras Toro, John Bruce Patterson, Warren Stanfield Wade, Zoltan Zubovics, Yun Yang, Zhipeng Wu
  • IRE-1? inhibitors
    Patent number: 9981901
    Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts thereof. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response and can be used as single agents or in combination therapies.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: May 29, 2018
    Assignee: FOSUN ORINOVE PHARMATECH, INC.
    Inventors: John B. Patterson, David G. Lonergan, Gary A. Flynn, Qingping Zeng, Peter V. Pallai